Ignite Creation Date:
2025-12-25 @ 3:27 AM
Ignite Modification Date:
2025-12-26 @ 2:08 AM
Study NCT ID:
NCT01487005
Status:
UNKNOWN
Last Update Posted:
2012-06-11
First Post:
2011-12-01
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Cardiovascular Effects of Exposure to Ozone
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007249', 'term': 'Inflammation'}], 'ancestors': [{'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Blood'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 90}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2012-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2012-06', 'completionDateStruct': {'date': '2014-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2012-06-08', 'studyFirstSubmitDate': '2011-12-01', 'studyFirstSubmitQcDate': '2011-12-05', 'lastUpdatePostDateStruct': {'date': '2012-06-11', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2011-12-07', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2014-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in endothelial function', 'timeFrame': 'Baseline (16 hours before exposure) and 4 hours after exposure', 'description': 'Brachail artey flow-mediated dilation and nitroglycerin-mediated dilation'}, {'measure': 'Change in heart rate variability', 'timeFrame': 'Baseline (0.5 hours before exposure) and 0.2, 2, and 21.5 after exposure', 'description': 'measured with Holter monitor'}, {'measure': 'Change in prothrombotic vascular state', 'timeFrame': 'Baseline (17 hour before exposure) and 3.5 and 22 hours after exposure', 'description': 'Peripheral blood samples will be taken and stored as plasma for measurement of von Willenbrand Factor antigen'}, {'measure': 'Change in cardiac repolarization', 'timeFrame': 'Baseline (0.5 hours before exposure) and 0.2, 2, and 21.5 after exposure', 'description': 'from Holter monitor'}], 'secondaryOutcomes': [{'measure': 'Change in markers of systemic inflammation', 'timeFrame': 'Baseline (17 hour before exposure) and 3.5 and 22 hours after exposure', 'description': 'Peripheral blood samples will be taken and stored as plasma for measurements of inflammatory markers'}, {'measure': 'Change in lung function', 'timeFrame': 'Baseline (0.2 hours before exposure) and 0.5, 3, and 22.5 hours after exposure', 'description': 'Spirometry'}, {'measure': 'Lung inflammation', 'timeFrame': '22 hours after exposure', 'description': 'A sputum sample will be obtained and stored for measurement of inflammatory mediators'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['ozone', 'air pollution', 'vascular function', 'cardiac function', 'inflammation'], 'conditions': ['Cardiovascular Injury']}, 'referencesModule': {'references': [{'pmid': '32125874', 'type': 'DERIVED', 'citation': 'Rich DQ, Thurston SW, Balmes JR, Bromberg PA, Arjomandi M, Hazucha MJ, Alexis NE, Ganz P, Zareba W, Thevenet-Morrison K, Koutrakis P, Frampton MW. Do Ambient Ozone or Other Pollutants Modify Effects of Controlled Ozone Exposure on Pulmonary Function? Ann Am Thorac Soc. 2020 May;17(5):563-572. doi: 10.1513/AnnalsATS.201908-597OC.'}, {'pmid': '29232153', 'type': 'DERIVED', 'citation': 'Arjomandi M, Balmes JR, Frampton MW, Bromberg P, Rich DQ, Stark P, Alexis NE, Costantini M, Hollenbeck-Pringle D, Dagincourt N, Hazucha MJ. Respiratory Responses to Ozone Exposure. MOSES (The Multicenter Ozone Study in Older Subjects). Am J Respir Crit Care Med. 2018 May 15;197(10):1319-1327. doi: 10.1164/rccm.201708-1613OC.'}]}, 'descriptionModule': {'briefSummary': 'The Multicenter Ozone Study in Elderly Subjects will investigate whether short-term exposure of elderly volunteers to ambient levels of ozone in a controlled exposure setting causes acute cardiovascular responses as assessed by changes in blood pressure, cardiac function, and systemic biomarkers of inflammation, endothelial dysfunction, and thrombosis.', 'detailedDescription': 'This multicenter study will investigate whether short-term exposure of elderly volunteers to ambient levels of O3 in a controlled exposure setting while intermittently exercising causes acute cardiovascular responses. The study is based on the suppositions that: 1) elderly people are a susceptible group for cardiovascular effects; and 2) effects are more likely with exercise.\n\nThe study will involve approximately 90 healthy volunteers aged ≥55 and ≤70 who meet strict criteria for inclusion. They will be exposed for 3 hours to clean air, 0.07 ppm O3 (near the current NAAQS), and 0.12 ppm O3 (a level measured in several locations in the US). A suite of cardiovascular and pulmonary endpoints will be measured on the day before the exposure and up to 22 hours after the exposures. The study is being conducted at three centers using a common protocol and common SOPs. Most the endpoints will be analyzed by core laboratories to reduce the variability in the results. A Data Coordination and Analysis Center will assemble all the data generated by the three centers and conduct the statistical analyses on the combined data sets.\n\nThe study has 3 main objectives:\n\n1. To determine the relationship of altered autonomic balance (measured as changes in heart rate and heart rate variability (HRV)), cardiac arrhythmia, and repolarization and ozone exposure.\n2. To identify instances of altered systemic vascular function \\[measured as brachial artery flow-mediated dilation (FMD)without and with nitroglycerin (NTG) when exposed to ozone.\n3. To identify pro-thrombotic vascular state (measured as increase in von Willebrand factor antigen in blood - primary endpoints) when exposed to ozone.\n\nAdditional objectives include:\n\n1. To identify any increase in micro particle-associated tissues factor (measured as number of particles and tissue factor activity) and platelet activation) in ozone exposure.\n2. To identify if markers of systemic oxidative stress and inflammation and any correlation with the cardiovascular effects and degree of airway injury (measured as CC16) and airway inflammatory effects (neutrophils and cytokines in induced sputum) in ozone exposure.\n3. To determine if cardiovascular effects in ozone exposure are correlated with airway inflammatory effects, but not lung function effects.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '55 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Healthy elderly volunteers living in or around San Francisco, CA, Research Triangle Park, NC, and Rochester, NY', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* males and females of all ethnic backgrounds.\n* Normal spirometry (FEV1 and FVC \\>75% of predicted and FEV1/FVC \\>0.65).\n* Ability to complete the exposure exercise regimen chosen to induce a ventilation rate of 15 to 17 L/min/m2 without exceeding 80% of predicted maximal heart rate.\n* Normal baseline 12-lead resting ECG, and absence of significant ST depression while performing the 15-minute required level of exercise targeted for the exposure period.\n* Subjects must be able to avoid certain medication supplements listed for 1 week before the exposure.\n\nExclusion Criteria:\n\n* Non-English speaking.\n* Including, but not limited to as ascertained by the physicians: Subjects with chronic cardiovascular (such as ischemic heart disease) or respiratory (such as asthma or COPD) disease; diabetes, or other organ or system dysfunction; cerebrovascular disease; active psychiatric disorders that would interfere with the subject's ability to understand and participate in the study. Subjects who have tested positive for a disease that affects the immune system (such as HIV, lymphoma, leukemia) or current drug or alcohol abuse (defined as having more than 3 drinks per day or being unable to abstain from alcohol for 3 days).\n* Subjects with atopy or allergic rhinitis will not be excluded as long as they do not require regular treatment with antihistamines or systemic steroids.\n* Ever-smokers (smoked tobacco or marijuana during the last five years, or with history of \\>10 pack year for tobacco or \\> 1 joint year for marijuana, or living with a smoker who smokes inside the house).\n* Subject having plasma cotinine level \\> 3ng/mL.\n* BMI \\>35 or \\<18 (35 is the official cut off for class 1 obesity).\n* Hypertension (defined as blood pressure \\>140 systolic or \\>90diastolic) or on anti-hypertension medications other than diuretics.\n* Pregnancy or nursing (breastfeeding).\n* On the following medications: prednisone, statins, beta-blockers, anticoagulants, current hormonal therapy, tamoxifen. Subjects will not be asked to discontinue needed prescription medications for the purpose of this study. If any of these medications becomes necessary during the course of the study, the subjects will be excluded. Use of other medications will be considered on an individual basis.\n* Subjects taking aspirin or PDE5 inhibitors must be willing to abstain from these medications during the week preceding each exposure.\n* Occupational exposures (exposed to high levels of vapors, dust, gases, or fumes on an on-going basis)"}, 'identificationModule': {'nctId': 'NCT01487005', 'acronym': 'MOSES', 'briefTitle': 'Cardiovascular Effects of Exposure to Ozone', 'organization': {'class': 'OTHER', 'fullName': 'Health Effects Institute'}, 'officialTitle': 'Multicenter Ozone Study in Elderly Subjects', 'orgStudyIdInfo': {'id': '10-01-4'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'elderly subjects', 'description': 'Healthy'}]}, 'contactsLocationsModule': {'locations': [{'zip': '94143', 'city': 'San Francisco', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Hofer Wong', 'role': 'CONTACT', 'email': 'howong@sfghoem.ucsf.edu', 'phone': '415-206-8951'}, {'name': 'John Balmes, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of California at San Francisco', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '02472', 'city': 'Watertown', 'state': 'Massachusetts', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United States', 'facility': 'New England Research Institutes, Inc.', 'geoPoint': {'lat': 42.37093, 'lon': -71.18283}}, {'zip': '14642', 'city': 'Rochester', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Erika Little', 'role': 'CONTACT', 'email': 'erika_little@urmc.rochester.edu', 'phone': '585-275-4163'}, {'name': 'Mark Frampton, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Rochester', 'geoPoint': {'lat': 43.15478, 'lon': -77.61556}}, {'zip': '27599', 'city': 'Chapel Hill', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Martha Almond', 'role': 'CONTACT', 'email': 'martha_almond@med.unc.edu', 'phone': '919-966-0759'}, {'name': 'Philip Bromberg, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of North Carolina at Chapel Hill', 'geoPoint': {'lat': 35.9132, 'lon': -79.05584}}], 'centralContacts': [{'name': 'Maria G Costantini, PhD', 'role': 'CONTACT', 'email': 'mcostantini@healtheffects.org', 'phone': '617-488-2302'}], 'overallOfficials': [{'name': 'Anne Stoddard, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Carelon Research'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Health Effects Institute', 'class': 'OTHER'}, 'collaborators': [{'name': 'Carelon Research', 'class': 'OTHER'}, {'name': 'University of California, San Francisco', 'class': 'OTHER'}, {'name': 'University of North Carolina, Chapel Hill', 'class': 'OTHER'}, {'name': 'University of Rochester', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}